Neogenix Oncology, Inc. is pleased to announce it has signed an agreement with Cambridge Biomedical, Inc, based in Boston, MA, for the development of its pancreatic and colorectal cancer diagnostic serum ELISA assays. Cambridge Biomedical provides core expertise in assay optimization and validation within an FDA recognized laboratory that is CLIA certified and CAP accredited. Neogenix has developed tumor specific biomarkers for the detection of pancreatic and colorectal cancer in tissue and serum. The ELISA assay utilizes the Neogenix patent protected therapeutic monoclonal antibodies (NEO-101, NEO 201, NEO 301) . These diagnostic assays will serve as the companion products for the Neogenix anti-cancer mAb therapeutic pipeline and hold additional hope for early detection of pancreatic and colorectal cancer.
Dr. Philip M. Arlen, CEO and President of Neogenix Oncology, said, "This represents a critical milestone for Neogenix as we aim to validate our companion diagnostic biomarkers for performance within a CAP/CLIA laboratory environment. We are extremely excited about our partnership with Cambridge Biomedical. They bring a highly experienced and fully integrated team in both assay development and diagnostic services."
"Neogenix's therapeutic antibodies and companion diagnostic products are potentially significant steps towards the early detection and treatment of pancreatic and colorectal cancer. Cambridge Biomedical is proud to be able to apply its analytical and regulatory expertise to accelerate the commercialization process to make these much needed products available to afflicted patients," said Dr. John J. Reddington, COO of Cambridge Biomedical Inc.
New trials show promise for immune checkpoint blockers in early-stage lung cancer